Bod Australia has announced strong sales growth in the second half of 2020, filling 3,941 prescriptions for its MediCabilis product during the six-month period, a 91% increase on the first half of the year and a 114% increase on H2 2019.

Bod has now filled more than 8,000 MediCabilis prescriptions since July 2019.

The company attributed the growth to continued product uptake and strong brand recognition in Australia, as well as the nationwide clinical observational study it undertook in 2020. Bod has also progressed a number of educational initiatives with Australian prescribers which have boosted sales.

Repeat prescriptions during the second half of CY2020 accounted for 62% of the volume.

Cumulative MediCabilis units sold on a month-by-month basis.

CEO Jo Patterson said: “MediCabilis is commonly prescribed for a range of chronic conditions, but most noticeably chronic pain and anxiety.

“To treat these kinds of conditions, patients will always require a GMP pharmaceutical grade, standardised and consistent product. This is one of the key competitive advantages of MediCabilis and one of the reasons behind the company’s strong repeat prescription growth.”

She said she expected strong demand to continue across Australia, further boosting revenue.